EGFR TKI were granted orphan drug status by the European Medicines Agency for the treatment of HNSCC in the setting of Fanconi Anemia based on promising findings in cell line xenograft studies [39]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.